Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
Abstract
Prostate cancer is the second leading cause of male cancer deaths. Castration-resistant prostate cancer (CRPC) is a lethal stage of the disease that emerges when endocrine therapies are no longer effective at suppressing activity of the androgen receptor (AR) transcription factor. The purpose of this study was to identify genomic mechanisms that contribute to the development and progression of CRPC.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 15, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-3023
Entities
People
- Benjamin Auch
- Christine M Henzler
- Christopher A. Maher
- Claudia Bertan
- Colm Morrissey
- Courtney N Passow
- Daniel Nava Rodrigues
- David A. Quigley
- Felix Y. Feng
- Ha X. Dang
- Johann de Bono
- Michael Fraser
- Rendong Yang
- Scott M Dehm
- Stephen R Plymate
- Suzanne Carreira
- Tae Hyun Hwang
- Yeung Ho
- Yingming Li
Organizations
- Cleveland Clinic
- National Institutes of Health
- Ontario Institute for Cancer Research
- Prostate Cancer Foundation of Australia
- United States Department of Defense
- University of California
- University of California, San Francisco
- University of Minnesota
- University of Washington
- VA Puget Sound Health Care System
- Washington University in St. Louis